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Systematic Review
Tissue Engineering and Regenerative Medicine Strategies in
Meniscus Lesions
Hélder Pereira, M.D., Ana M. Frias, C.Eng., Ph.D., Joaquim Miguel Oliveira, B.Sc., Ph.D.,
João Espregueira-Mendes, M.D., Ph.D., and Rui Luís Reis, C.Eng., M.Sc., Ph.D.
Purpose: The aim of this systematic review was to address tissue engineering and regenerative medicine
(TERM) strategies applied to the meniscus, specifically (1) clinical applications, indications, results, and pitfalls
and (2) the main trends in research assessed by evaluation of preclinical (in vivo) studies. Methods: Three
independent reviewers performed a search on PubMed, from 2006 to March 31, 2011, using the term
“meniscus” with all of the following terms: “scaffolds,” “constructs,” “cells,” “growth factors,” “implant,”
“tissue engineering,” and “regenerative medicine.” Inclusion criteria were English language–written, original
clinical research (Level of Evidence I to IV) and preclinical studies of TERM application in knee meniscal
lesions. Reference lists and related articles on journal Web sites of selected articles were checked until
prepublication for potential studies that could not be identified eventually by our original search. The modified
Coleman Methodology score was used for study quality analysis of clinical trials. Results: The PubMed search
identified 286 articles (a similar search from 2000 to 2005 identified 161 articles). Non–English-language
articles (n 9), Level V publications (n 19), in vitro studies (n 118), and 102 studies not related to the
topic were excluded. One reference was identified outside of PubMed. Thirty-eight references that met the
inclusion criteria were identified from the original search. On the basis of our prepublication search, 2 other
references were included. A total of 9 clinical and 31 preclinical studies were selected for further analysis. Of
the clinical trials, 1 was classified as Level I, 2 as Level II, and 6 as Level IV. Eight referred to acellular scaffold
implantation for partial meniscal replacement, and one comprised fibrin clot application. The mean modified
Coleman Methodology score was 48.0 (SD, 15.7). Of the preclinical studies, 11 original works reported on
studies using large animal models whereas 20 research studies used small animals. In these studies the
experimental design favored cell-seeded scaffolds or scaffolds enhanced with growth factors (GFs) in attempts
to improve tissue healing, as opposed to the plain acellular scaffolds that were predominant in clinical trials.
Injection of mesenchymal stem cells and gene therapy are also presented as alternative strategies. Conclusions:
Partial meniscal substitution using acellular scaffolds in selected patients with irreparable loss of tissue may be
a safe and promising procedure. However, there is only 1 randomized controlled study supporting its
application, and globally, many methodologic issues of published trials limit further conclusions. We registered
a different trend in preclinical trials, with most considering augmentation of scaffolds by cells and/or GFs, as
opposed to the predominantly acellular approach in clinical trials. Different TERM approaches to enhance
meniscal repair or regeneration are in preclinical analysis, such as the use of mesenchymal stem cells, gene
therapy, and GFs alone or in combination, and thus could be considered in the design of subsequent trials. Level
of Evidence: Level IV, systematic review of Level I to IV studies.
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The advent of tissue engineering (TE) promises torevolutionize the concept of medicine by using
strategies mimicking the mechanisms underlying nor-
mal tissue formation and regeneration. As stated by
Langer and Vacanti,1 TE is the field of research that
envisions the use of both “principles of engineering
and life sciences towards the development of biolog-
ical substitutes to restore, maintain, or improve tissue
function.” TE strategies, by definition, make use of 3
main variables, that is, scaffolds, cells (differentiated
or undifferentiated), and bioactive agents or growth
factors (GFs), that can be implanted into the damaged
site, alone or in combination. On the other hand,
regenerative medicine is a wider concept, and besides
comprising the use of soluble molecules and stem cell
technology, it also can apply TE and gene therapy
strategies to restore or establish normal functions of
cells/tissues/organs. Given the pivotal roles of the
meniscus in knee homeostasis and proper joint
function/stability, the development of regenerative
treatments as an alternative to meniscectomy or tradi-
tional repair procedures has been attempted.
“Nothing has changed so much in knee treatment
and surgery as the meniscal treatment algorithms.”
This statement from René Verdonk2 perfectly summa-
rizes the overturn that has occurred in the approach
toward meniscus lesions in recent years. The wedge-
shaped semilunar disks of fibrocartilaginous tissue
that characterize menisci play critical roles in knee
joint biomechanics. In fact, it has been recognized that
their removal determines deleterious joint conse-
quences, particularly in the long-term.3,4
The biologic characterization of meniscus tissue,
though not yet completely accomplished, has evolved
significantly in the last few years. This is true con-
cerning recognition of different cellular populations,
understanding its ultrastructure,5 cells and extracellu-
lar matrix segmental distributions, biomechanical
properties, biologic interactions, or injury response
mechanisms.
The need for meniscal repair/regeneration is in-
creasingly appreciated, with growing calls appealing
for the need to “save the meniscus.”6 When repair is
no longer possible, substitution seems to be the most
adequate answer,7 with growing experience and con-
sensus around meniscal allograft transplantation for
whole meniscal replacement in selected cases. More-
over, meniscal lesions, in their various forms, subsist
as 1 of the most frequent injuries leading to orthopae-
dic surgery.8 Considering the significant socioeco-
nomic impact and the scarcity of reliable clinical
solutions, it is evident that meniscal repair urgently
requires the development of new effective strategies.8
The general clinical community (orthopaedic sur-
geons included) has increasingly recognized the rele-
vance of basic science and tissue engineering and
regenerative medicine (TERM)–related research9 in
opening up a new world of perspectives to deal with
some health-related problems. Being that meniscal
repair/regeneration is a hot topic in orthopaedics and,
more recently, in the field of TERM, the great ad-
vances in meniscal research should be reviewed to
fully comprehend its progress and potential impact on
clinical practice.
The purpose of this review is to summarize the
hierarchy of studies dealing with TERM strategies
applied to the meniscus while providing a systematic
narrative that will enable clinicians/experts to become
familiar with the most recent developments in this
field. Thus we review relevant information related to
(1) clinical applications, indications, results, and pit-
falls and (2) the main research directions in the field of
meniscal repair/regeneration assessed by evaluation of
preclinical (in vivo) studies.
Besides establishing the state of the art of clinical
application within this topic, we aim to summarize
relevant preclinical information, thus facilitating the
final step of translating research from bench to bedside
in the nearby future and helping the “recently recog-
nized” orthopaedic clinician-scientists10,11 in design-
ing valid research projects.
METHODS
Three independent reviewers performed a search on
PubMed for original works published from 2006 to
March 31, 2011, using the term “meniscus” with all of
the following terms: “scaffolds,” “constructs,” “cells,”
“growth factors,” “implant,” “tissue engineering,” and
“regenerative medicine.” A second search period
(2000 to 2005) was considered to assess the evolution
of interest in this topic reflected in the number of
publications.
Inclusion criteria were the following: English
language–written, original clinical and preclinical
(in vivo) studies of TERM application in knee me-
niscal lesions published from 2006 to March 2011.
All abstracts were evaluated; only Level I to IV clin-
ical studies were considered.
The full-text article was reviewed; reference lists
and related electronic libraries checked until prepub-
lication period for screening relevant studies that
could not be identified eventually by our original
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search. Articles were classified by levels of evidence,
according to the 5-level system.12 Clinical studies’
quality analysis was assessed with the Coleman Meth-
odology score as modified by Kon et al.13 In addition,
preclinical studies were also considered to assess
promising research trends aiming for clinical applica-
tion. All articles identified by these search terms were
manually reviewed and discussed among us, and a
decision was made regarding inclusion or exclusion.
In the absence of agreement among us, the final de-
cision was made by the senior author (R.L.R.).
RESULTS
By use of the described method in the period 2000 to
2005, 161 articles were identified, whereas from 2006 to
March 2011, this number increased to 286 (Table 1).
From the last group of articles (n  286), 102 were
excluded because they were classified as not specifically
addressing the topic. In addition, non–English-language
articles (n 9) and Level V publications (n 19) were
eliminated. No previous systematic review was found
relating this topic. Early-stage in vitro studies (n 
118) dealing with cell culturing and cytotoxicity
screening of materials were also excluded. One refer-
ence was identified by checking reference lists and
searching in related libraries or journal Web sites.
Considering the inclusion and exclusion criteria, we
identified and selected 38 references14-51 from the
original search for further analysis. Two other relevant
references were identified by the prepublication
search52,53 (Table 1).
Clinical Studies Using TE Strategies for Meniscus
Regeneration
For the clinical trials, we identified 1 as Level I,36 2
as Level II,29,47 and 6 as Level IV.16,20,22,46,51,52 Table
2 summarizes the clinical experience studies involving
the treatment of injured or degenerated meniscus. The
mean modified Coleman Methodology (MCM) score
for all TERM strategy trials was 48.0 (SD, 15.7).
Of the 9 clinical studies, 8 actually referred to
acellular scaffold implantation for partial meniscal
replacement (7 collagen based and 1 polyurethane
based). One of the clinical trials comprised fibrin clot
application (scaffold-GF approach) as an enhancer of
horizontal cleavage repair in the avascular zone.
The 7 published trials reporting on Collagen Meniscus
Implant (CMI) (currently known as Menaflex; ReGen
Biologics, Hackensack, NJ) application enrolled 565 pa-
tients; 487 were evaluated and 304 received CMI de-
vices, all for medial meniscus defects. The mean MCM
score of the CMI trials was 50.6 (SD, 12.6). One study
compared high tibial osteotomy (HTO) alone with
HTO combined with CMI.29 Two used partial menis-
cectomy patients as control groups.36,47 The remaining
studies were case series without control groups (Table
2). Control subjects comprised 167 partial meniscec-
tomies and 16 HTO procedures. The mean age re-
ported for CMI application ranged from 29.2 years52
to 41.8 years.29 One of the studies did not provide any
gender information,29 but in the remaining studies,
223 were men and 61 women. The mean follow-up
period ranged from 24 months29 to approximately 133
months.47,52 One trial reported results up to 24
months’ follow-up, but no central-tendency numeric
value was provided.20
Concomitant surgeries during CMI implantation
comprised 96 anterior cruciate ligament (ACL) recon-
structions,16,20,36,47,50,52 26 HTOs,16,20,29 7 microfrac-
tures,16,20,46,47,52 and 2 autologous chondrocyte im-
plantations20 for chondral lesions up to grade III.
Five trials considered a division in 2 groups of
candidates for the implant: (1) acute irreparable me-
niscal lesions and (2) a chronic arm with prior tissue
loss.16,20,36,46,47 Only 2 provided some information on
meniscal tear type.16,52 Scarce information was pro-
vided regarding previous surgeries in terms of time to
index surgery and type of surgery.36,46,52 In the study
considering CMI use in HTO candidates, no informa-
tion on preoperative or postoperative varus-valgus
alignment was provided for either cases or control
subjects.29
TABLE 1. Summary of Search Strategy, Exclusion
Criteria, and Evidence Level of Identified Articles
Initial search terms from 2000 to 2005 161
Initial search terms from 2006 to 2011 286
Exclusion of studies not related to topic
(or not proposing specific approach to
meniscus) 102
Exclusion of non–English-language studies 9
Exclusion of in vitro studies 118
Level V studies (case report, authors’
opinion, nonsystematic review) 19
References not identified by PubMed 1
Clinical (Level I-IV) studies included
based on original search 8
Preclinical (in vivo) studies included based
on original search 30
Articles identified from prepublication
search (preclinical and clinical) 2
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The time interval between injury, onset of symp-
toms, or prior meniscectomy surgeries and implanta-
tion was poorly defined or not defined at all.
Several different clinical scoring systems were
used. In decreasing order of frequency, these were the
Lysholm score (n  5),16,29,36,47,52 subjective visual
analog scale for pain (n  5),29,36,46,47,52 Tegner ac-
tivity level score (n  3),16,36,47 International Knee
Documentation Committee objective form (n 2)46,47
and subjective form (n  1),29 Cincinnati knee rating
scale (n  1),46 and Short Form 36 score (n  1).47
The preoperative Tegner score was based on patient
recall in 2 trials.36,47 One study using magnetic reso-
nance imaging (MRI) evaluation did not present clin-
ical outcome.20 Besides this variety, scarce numeric
data presentation (including lack of or scarce statisti-
cal dispersion measure presentation) for descriptive
statistics and clinical outcome in all trials limited
global outcome analysis.
Four studies included independent radiographic
evaluation16,46,47,52: one used the Kellgren-Lawrence
score,16,46 another compared joint space narrowing of
the operated knee with the healthy contralateral
knee,47 Monllau et al.52 used the Ahlbäck classifica-
tion, and no specific method was referred to in the
fourth.46
MRI evaluation was reported in 5 trials.16,20,46,47,52
Genovese et al.20 described an MRI score of 1 to 3
degrees, where a higher score more closely resembles
the normal meniscus considering morphologic and
signal features. This was used in 3 subsequent stud-
ies.16,47,52 Genovese et al. also proposed MRI arthrog-
raphy evaluation for better chondral lesion assessment
(in 2 cases conventional MRI failed to distinguish
chondral lesions detected only through arthrography),
which was also considered by Bulgheroni et al.16 Four
trials presented results of second-look arthroscopies in
a total of 187 patients.16,20,29,46 The mean length of
CMI applied was reported in 3 trials, ranging from 3.6
to 4.8 cm.16,47,52 An increase in total tissue area,
considering the existing meniscus rim at index surgery
and the new tissue formed registered on second-look
examination, was also described.36 Biopsies were per-
formed in 149 patients from 2 trials.16,36 Despite this,
no specific score or histologic objective evaluation
method was used. The outcome relies mainly on vi-
sual estimates or generic conclusions of histologic
evaluation without consideration of a reproducible
method.
Considering failure as the inability to identify the implant
on MRI, 7 cases of failure were described.20,46,47,52 One of
these was reoperated on for removal of remnants, and
second-look arthroscopy confirmed the diagnosis.20 No
further considerations were provided for the others.
Besides this, 6 others were removed (totaling 7): 1 for
disorganization,52 1 for disorganization and luxa-
tion,29 2 for early failure16,36 (1 patient did not comply
with rehabilitation16), 1 for infection,36 and 1 for un-
reported cause.36
Reoperations were needed in 8 patients because of
effusion and/or pain, stiffness, locking, or instabil-
ity.36,47,52 Reoperation related to the implantation
comprised 1 case of entrapment of the saphenous
nerve’s infrapatellar branch requiring neurolysis.16
Thus a total of 15 of 282 patients were reoperated on
for complications considered as possibly related to the
described method.
Salvage procedures included arthroscopic debride-
ment/lavage alone or in combination,16,20,29,36,46,47
HTO,36,47,52 ACL repair,36 partial meniscectomy,36
and meniscal allograft transplantation.52
Reduced implant size with time was reported in all
trials assessed by MRI or second-look arthroscopy.
However, the correct incidence of this fact was not
possible to determine because it was not specifically
addressed with regard to either its magnitude or its
influence in the outcome.
No clinically relevant data on severe inflammation
or immune response were found in any of the biopsy
specimens reported on.
Only 1 multicenter, Level IV, single-armed study,
with 52 patients, reports on clinical experience with a
polyurethane-based implant (Actifit; Orteq, London,
England).51 There were 39 male patients and 13 fe-
male patients, with a mean age of 30.8 years (SD, 9.4
years), and 34 medial and 18 lateral meniscus lesions,
with a mean longitudinal length of 47.1 mm. No
clinical outcome was presented (the authors proposed
to assess tissue ingrowth and safety) using indepen-
dent MRI analysis (blinding to clinical data) including
dynamic contrast-enhanced MRI (method to assess
tissue vascularization).
Qualitative histologic analysis was presented in 44
of 52 cases. At 12 months, 1 case of no integration of
the scaffold with the native meniscus was registered.
Regarding registered complications at 12 months’
follow-up, a postoperative infection developed in 1
patient (1 week after index surgery, the scaffold was
removed as part of the treatment); 1 patient was sub-
mitted to a total knee arthroplasty 4 months after the
implant placement (considered an error of inclusion
for severe osteoarthritis since the beginning); and 1
patient had a myocardial infarction. All these compli-
cations were classified as not related to the scaffold.
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One trial proposed a fibrin clot approach to broaden
the indication for repair of horizontal cleavage tears in
avascular-zone cases.24 The defect was filled with
fibrin clots before tightening the sutures in a “sand-
wich fashion.” This series initially reported on 3 me-
dial and 6 lateral menisci. Generic conclusions regard-
ing improvement in functional scores are presented,
but the Lysholm score was accessible for only a single
patient.
Preclinical Studies Using TE Strategies for
Meniscus Regeneration
To organize data for our analysis, preclinical reports
(n  31) were grouped considering the animal model
used, that is, large or small animals (Tables 3 and 4).
The stream of research considers the following: strat-
egies aiming to enhance suture repair, total or partial
replacement, and percutaneous therapies to increase
tissue repair or decrease degradation rate. Among the
31 preclinical studies related to this topic, 11 reports
used large animal models such as swine, sheep, and
goats (Table 3). From Table 3, it is possible to observe
that 4 studies focused on the use of an acellular
scaffold17,30,50,53 and 6 studies used either alloge-
neic41,42 or autologous27,31,41 cells with scaffolds or
scaffolds combined with GFs (vascular endothelial
growth factor [VEGF]).28,34 A gene therapy approach
was also used in 1 study by combining an injectable
alginate gel with transfected bone marrow cells with
human insulin-like growth factor 1 (hIGF-1).49
Twenty studies using small animal models (e.g.,
mice, rats, rabbits, and dogs) were identified (Table 4).
These studies were mainly focused on TE strategies
comprising the use of acellular scaffolds and cell-
scaffold constructs.
Combining all preclinical articles from Tables 3 and 4,
it can be seen that 11 works were focused on acellular
scaffold approaches,17-19,21,30,35,39,40,44,50,53 9 tested a
cell-seeded scaffold approach,15,25,27,31,37,41-43,45 and 2
studies tested a combination of cell-scaffold GFs,26,49
1 of which also used gene therapy.49 In addition, 1
study compared cell-seeded scaffold and scaffold-GF
approaches,48 and another tested the immunocompat-
ibility of a scaffold in vivo (decellularized porcine
meniscus) but describe the intention for future cell-
seeded construct approach.38 Three studies tested a
combination of scaffold-GFs,23,28,34 3 proposed in-
jected mesenchymal stem cells (MSCs),14,22,32 and 1
presented only a gene therapy approach33 in preclini-
cal experiments. Figure 1 illustrates the heterogeneity
and the number of articles using the different treat-
ment strategies in both clinical and preclinical studies.
Whereas most clinical trials deal with acellular scaf-
fold implantation alone for partial replacement of ir-
reparable meniscus defect (8 of 9 studies), the same
trend is not present in preclinical research works. In
the latter group, most studies involving the application
of scaffolds (n 27) favor its use in combination with
cells (constructs) or with GFs (16 of 27).
DISCUSSION
Most patients reported on in the clinical studies are
aged in their 30s to 50s, within an age related to higher
working productivity. Bearing this fact in mind, one
can extrapolate important consequences in lost days at
work and the relevant socioeconomic impact of me-
niscal lesions. In such a young population, we can
commonly expect good cartilage status for stable (or
stabilized) knees with meniscal lesions. Therefore this
represents the ideal target to defend meniscus function
to prevent early joint degeneration. The Multicenter
Orthopaedic Outcomes Network (MOON), using from
a large prospective cohort of relatively young patients
undergoing ACL reconstruction, has concluded that
there is a large potential market for meniscus-related
TERM strategies through scaffolds, advancing repair
to the avascular zone, or performing all-biologic re-
pairs without implants.54 For all the aforementioned
reasons, this is a subject requiring attention from the
knee-surgeon community, and significant socioeco-
nomic impact can be expected from cost-effective
strategies in this area. Certainly, this requires master-
ing a new field of knowledge and its specific language.
Development of new TERM trends requires the com-
bined effort of several areas, such as clinical ortho-
paedics, veterinary medicine, biochemistry, biology,
and TE or regenerative medicine, but assessing basic
science reports is not always easy for clinicians. In
turn, to help bring research from bench to bedside,
clinicians must help develop novel strategies to orga-
nize and stratify knowledge and strengthen the bonds
with basic science researchers.
Clinical Studies Using TE Strategies for Meniscus
Regeneration
In all 8 clinical studies reporting on scaffold im-
plants, we can find global consensus about indications
unrelated to the material applied that we can summa-
rize as (1) irreparable traumatic or degenerative loss of
meniscus tissue with preserved anterior and posterior
meniscus insertions and preserved peripheral rim; (2)
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biologically young patients; and (3) stable or surgi-
cally stabilized knees. Similarly, we can do the same
for exclusion criteria: (1) posterior cruciate ligament
insufficiency of the involved knee; (2) advanced uni-
compartmental or global degenerative cartilage dis-
ease in the affected joint; (3) uncorrected axial mis-
alignment in the lower extremity; (4) inflammatory
arthritis or autoimmune diseases; and (5) active infec-
tion or neurologic conditions that would limit rehabil-
itation compliance. In controlled studies control sub-
jects who had undergone partial meniscectomy
followed a different rehabilitation program than im-
planted patients,29,36,47 and this was not clearly de-
fined for HTO patients.29 This fact might influence
short-term outcome, but we do have to agree with
previous researchers that this is probably irrelevant
with longer follow-up.47 From our analysis, we could
not conclude which control subjects were best suited
to evaluate partial meniscal replacement strategies,
that is, partial meniscectomy or HTO patients.
The variety of clinical scores used and paucity of
numerical data provided impaired global assessment
of results. This issue should be considered in subse-
quent trials.
All studies considering Menaflex/CMI presented
some degree of outcome improvement compared with
preoperative status.16,20,29,36,46,47,52 Compared with HTO
alone, Linke et al.29 found no significant differences.
Zaffagnini et al.47 and Rodkey et al.,36 using partial
medial meniscectomy (PMM) controls, could not estab-
lish significant differences for Lysholm scores. Consid-
ering pain in CMI cases, 1 study could not find signifi-
cant differences,36 but significantly lower scores have
been reported elsewhere.47
A new tool for outcome, the Tegner index (TI), was
proposed by Rodkey et al.36 (used also in 1 subsequent
study47) in an attempt to assess the percentage of activity
level loss that was regained as a result of treatment. It is
calculated by subtracting the preoperative Tegner score
from the latest score and then dividing this difference by
the result of subtracting the preinjury score from the
preoperative score. Significant improvement in the TI
was noticed in the series of Zaffagnini et al.47 and in the
chronic arm but not in the acute group at latest follow-up
in the trial of Rodkey et al. Besides these 2 studies,36,47
we could not identify any other report validating TI as a
measurement tool for the amount of activity loss that was
regained after the procedure. Furthermore, in these trials
preoperative Tegner score was based on patient recall,
and thus an inherent bias must be considered.
The score described by Genovese et al.20 for MRI
evaluation has subsequently been used, facilitating
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global analysis. The new tissue seems to mature pro-
gressively over time. However, basic features and
volumetric characteristics of the obtained tissue com-
prise a critical issue once poorly understood.
Biopsies have been described based on generic es-
timates. Objective histologic evaluation topics capable
of being reproduced among series would be useful.
The new tissue obtained was described as not pure
fibrocartilage but a hybrid repair tissue with some
similarities.36
Early failure of implants because of dislocation or
resorption has been reported, although infrequently. A
decrease in the size of the implant to some extent was
often reported, even if the implication in terms of
clinical outcome remains unclear. Some concerns
about initial lower mechanical properties have also
been reported.45
Another consistent finding from all trials is the
absence of a specific clinically relevant inflammatory
or immune response to the scaffold. The only study
reporting on polyurethane-based implant (Actifit) ap-
plication intended to assess whether the implant is
biocompatible, biomimetic, and biodegradable, in ad-
dition to its safety profile.51 However, no clinical
outcome was provided.
The length and characteristics of treated defects are
similar to available data regarding the CMI. The in-
clusion of dynamic contrast-enhanced MRI (method
to assess tissue vascularization) produced interesting
data, which could possibly also be used to evaluate
and compare with CMI (time and quality of integra-
tion). Qualitative histologic analysis was available for
84.6% of cases. Descriptive histologic results consider-
ing vascularization, cells, and extracellular matrix
(ECM) are provided. This includes a vascularized fibrous
capsule and 3 distinct layers. These results should also be
considered in subsequent studies. One case of early fail-
ure was reported, but similarly, no relevant immune or
inflammatory rejection was registered.
Despite positive MRI and histologic features, clin-
ical outcomes from randomized controlled trials are
needed before widespread application. Furthermore,
the availability of 2 such different scaffolds intended
for similar indications requires future clinical compar-
ison between them.
Using a completely different TERM approach, Ka-
mimura and Kimura24 reported on their clinical experi-
ence with an original method aiming to spread the indi-
cation of meniscal lesions to horizontal tears in the
avascular zone. Besides inherent innovation, finding the-
oretic support from basic science and having been clas-
sified originally as a Level IV study, this report should be
considered a Level V report because of the paucity of
objective clinical outcome data (MCM score, 19).
Preclinical Studies Using TE Strategies for
Meniscus Regeneration
TERM strategies aiming to enhance suture repair,
partial or total replacement of meniscus by use of
FIGURE 1. Number of published articles using
different treatment strategies in both clinical and
preclinical studies.
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scaffolds alone or in combination with cells and/or
GFs, and minimally invasive techniques to deliver
engineered cells have been addressed in in vivo mod-
els, as shown in Tables 3 and 4.
With respect to TERM strategies aiming to enhance
suture repair, Weinand et al.41,42 present an implant-
able biodegradable construct consisting of woven Vi-
cryl mesh (Ethicon, Somerville, NJ) seeded with ei-
ther allogeneic42 or autologous41 chondrocytes from
different tissues (articular, auricular, or costal). In
their work, it was hypothesized that combining a scaf-
fold with cells would favor suture of meniscal lesions
in the avascular zone.42 They further concluded that
the presence of both autologous and allogeneic chon-
drocytes enhances meniscal healing in a swine
model.41 Another possibility to solve analogous prob-
lems has been reported by Petersen et al.34 The local
application of VEGF through poly-(D,L-lactide) acid
(PDLLA)–coated sutures was proposed. Despite the
evidence that VEGF can significantly stimulate blood
vessel proliferation and healing of tears in the avas-
cular zone of the menisci, this study showed that the
local application of VEGF through PDLLA-coated
sutures failed to promote meniscus healing in Merino
sheep. More recently, Kopf et al.,28 testing similar
conditions, achieved analogous conclusions, raising
the explanation that PDLLA is probably inadequate as
a carrier. Cook and Fox18 proposed a polylactic acid
conduit with a central channel intended for fibrin clot
and cell carrier application. Their results suggest that
such an implant increases healing compared with
trephination plus suture alone. Another study tested 2
different possibilities for fixation of meniscal allograft
in rabbits: fibrin glue and octyl-cyanoacrylate.35 It was
observed that fibrin glue is not effective for fixation as
compared with suture and cyanoacrylate. Whereas
suture and octyl-cyanoacrylate adhesive have shown a
good performance for fixation, cyanoacrylate was in-
adequate for the proposed application because of the
severe inflammatory response.
TERM strategies aiming at total or partial replacement of
the meniscus have been exploited. Chiari et al.17 proposed a
hyaluronic acid (HYAFF; Fidia Advanced Biopolymers,
Abano Terme, Italy)–polycaprolactone scaffold with
promising initial results for meniscal repair and
substitution. Using a similar scaffold, Kon et al.27
have shown that constructs with autologous chon-
drocytes seem to improve results. Actually, the pres-
ence of a cartilaginous matrix in the cell-seeded scaf-
folds was observed, but no cartilaginous matrix was
present in the cell-free scaffolds. More recently, Zur et
al.50 proposed a nondegradable, acellular, Kevlar (E. I.
DuPont de Nemours and Co., Wilmington, DE) rein-
forced polycarbonate-urethane (PCU)–based scaffold.
This work showed that the artificial meniscal implant
delayed or even prevented osteoarthritic changes in the
knee joint after total medial meniscectomy, thus support-
ing the idea that replacement of the whole meniscus can
raise different issues compared with partial meniscal
defects alone.
Yamasaki et al.,45 using cell-seeded rat decellular-
ized meniscus scaffolds, concluded that constructs are
more effective than scaffolds alone. Similarly, Kang et
al.25 experimented with constructs using polygly-
colic acid scaffold in rabbits and found that regen-
eration of the whole meniscus was possible by the
TERM approach.
Tienen et al.40 found that polycaprolactone-polyure-
thane evokes less tissue reaction than Estane (BF
Goodrich Chemical N.V., Westerlo-Oevel, Belgium)
for acellular polyurethane-based meniscus implants.
These implants permitted tissue infiltration and differ-
entiation resembling the native meniscus but were not
capable of preventing cartilage degeneration. The au-
thors further stated the need for improvement of the
mechanical properties of their implants when intended
for total replacement. Welsing et al.,44 using a beagle
dog model as in the former study, showed that acel-
lular polycaprolactone-polyurethane implants also
could not avoid joint degradation.
Partial replacement raises an inherently different
challenge. Martinek et al.,31 using collagen-based me-
niscus implant for partial replacement, concluded that
constructs with autologous fibrochondrocytes perform
better than CMI alone. Similarly, Angele et al.15 found
that hyaluronan/gelatin composite scaffolds seeded
with stem cells perform better than empty scaffolds
and represent a valuable possibility aiming at repair of
meniscus defects.
A different approach aims to enhance scaffolds
associated with GFs. Ishida et al.23 described that
combining gelatin hydrogel with platelet-rich plasma
(PRP) as the carrier increased healing of meniscus
defects compared with either of them in isolation.
Considering the TERM triad, 1 study46 tested the use
of scaffold-GFs and cell-seeded scaffolds.48 Zellner et
al.48 compared the outcomes of PRP, hyaluronan-
collagen scaffold, and bone marrow as graft harvested
from the iliac crest of New Zealand white rabbits.
They concluded that neither bone marrow alone nor
PRP has an improved healing capacity relating to
acellular scaffold. However, bone marrow–MSC con-
structs performed better in terms of healing and inte-
gration48 as compared with all the previously men-
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tioned constructs. A different approach providing cells
and scaffold and including GFs was proposed by
Kobayashi et al.26 using meniscus fragments wrapped
with fascia sheaths, with promising results.
Nevertheless, acellular polyurethane scaffold in
partial defects is also capable of promoting tissue
ingrowth and protecting cartilage, as concluded by
Maher et al.30 In a dog model of large defects, Cook et
al.19 verified that acellular scaffold based on porcine
small intestinal submucosa provides better results than
meniscectomy. Scotti et al.37 showed the capacity of
fibrin gel embedded with articular chondrocytes to
increase bonding of meniscal tissue, providing initial
stability and permitting cell proliferation and differenti-
ation. Weinand et al.43 have evaluated a dynamic oscil-
lating cell-seeding technique in porous poly(lactic-co-
glycolic acid) scaffolds with subcutaneous implantation
in rats. This work has shown that auricular chondro-
cytes presented qualitatively better integration into
native meniscus tissue than articular and costal cell
implants. Stapleton et al.38 tested the immunocompat-
ibility profile of acellular porcine medial meniscus for
cell-based TERM applications, with promising results.
Despite the interesting results, a major problem in
meniscus total replacement remains unsolved; that is,
the need to stabilize or improve fixation of meniscus
polymeric implants still exists.
TERM strategies aiming at percutaneous tissue re-
pair/decreasing tissue degeneration have also been
attracting a great deal of attention. Injectable therapies
to achieve minimally invasive clinical application is
an attractive and promising technology. Zhang et al.49
investigated whether bone marrow stromal cells trans-
fected with the hIGF-1 gene encapsulated in calcium
alginate gel could improve the repair of full-thickness
meniscal defects in the avascular zone of the anterior
horn. The results support the efficacy of this approach
to deliver biologically effective concentrations of
hIGF-1 and suggested the value of liposome-mediated
ex vivo gene therapy for improving meniscus healing.
Injected synovial MSCs also can promote meniscal
repair without mobilization to distant organs as shown
by Horie et al.22 and Mizuno et al.32 Similarly, Agung
et al.14 tested a bone marrow–MSC injection approach
for treating meniscal partial defects. MSCs were ob-
tained from green fluorescent protein Sprague-Dawley
rats (transgenic). The researchers proposed that MSC
injection might be a valuable option for repair of
intra-articular injuries including meniscus injuries. A
completely different advanced regenerative medicine
perspective is presented by Ochiai et al.33 aiming to
reduce histologic meniscus degeneration. Heme oxy-
genase 1 isozyme is known to mediate oxidative stress
and is negatively influenced by Bach 1 transcription
factor. Their study shows increased antioxidant activ-
ity in Bach 1–deficient mice resulting in diminished
meniscus degeneration, thus suggesting a new stream
for research aiming to prevent osteoarthritis.
Our Opinion (Level V Evidence)
When the meniscus is damaged, spontaneous heal-
ing is rare and surgery is often required. Treatment of
meniscus lesions has been mainly limited to menis-
cectomy or partial repair by means of suturing in the
vascular zone. In the last few years, we have assisted
in making promising advances in the field of bioma-
terials and TERM. These breakthroughs have been so
disrupting that they can influence common medical
practice. Advanced regenerative solutions comprise
the use of stem cells and are currently impacting our
lives in a way never thought possible. Whereas most
clinical studies dealing with meniscal repair involve
the use of implants alone, such as Menaflex and Ac-
tifit, there is a growing interest in the assessment of
regenerative strategies based on cell-scaffold ap-
proaches in preclinical studies. Despite the difficulty
in translating such strategies to the clinical arena, the
use of cells or GFs combined with polymeric scaffolds
is now being envisioned and is under intensive re-
search. Thus it is our firm belief that future clinical
trials involving treatment of meniscus lesions will be
designed to contemplate the use of autologous cells
(e.g., stem cells) and GFs (e.g., PRP).
CONCLUSIONS
Interest in the literature on this subject is increasing,
but this is the first systematic review concerning
TERM clinical application and in vivo research for the
treatment of meniscus defects. Partial meniscal sub-
stitution by acellular scaffolds such as polyurethane
and collagen meniscus implants can be considered a
safe procedure in selected patients with irreparable
loss of tissue, with promising results. However, at
present, most preclinical studies are pointing out some
advantages to the enhancement of scaffolds with di-
verse cells, GFs, or both. Different TERM approaches
to increase repair and tissue replacement and mini-
mally invasive technologies including gene therapy
are in preclinical analysis, opening up other clinical
possibilities in the near future.
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